OncoSec Medical Culture d’entreprise

Mr. Tu Diep, M.Sc. has been Vice President of Operations at OncoSec Medical Incorporated since September 16, 2014. Mr. Diep has been a key member of OncoSec's core management team since its founding. He is responsible for leading corporate operations, including business development and licensing, commercial planning and maintaining his ongoing responsibilities in supporting clinical development of the Company's ImmunoPulse pipeline. Since joining OncoSec in March 2011, Mr. Diep has held positions of increasing responsibility, initially as Director of Corporate Communications and Development, where he managed the Company's communications strategy and supported the early development of the Phase II clinical trials. From there, he moved into the role of Executive Director of Clinical Development where he is integral in the management and execution of the ImmunoPulse program. Prior to joining OncoSec, he spent four years at Protox Therapeutics Inc. (now Sophiris Inc.), where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations and biologics manufacturing. Mr. Diep holds a masters of science in physiology from the University of Toronto.

Dr. Adil I. Daud, M.D. has been the Chief Clinical Strategist of OncoSec Medical Incorporated since April 2014. Dr. Daud is a professor of medicine at the University of California San Francisco and a nationally recognized expert in early phase drug development in skin cancer and solid tumors. Dr. Daud served as Medical Director of Moffitt Affiliate Research, H. Lee Moffitt Cancer Center, Tampa, Florida. He has been the Chairman of Melanoma Advisory Board at OncoSec Medical Incorporated since February 2013. He serves as a Member of Clinical and Scientific Advisory Board at OncoSec Medical Incorporated. He served as a Member of Scientific Advisory Board at Altor BioScience Corporation. He is a Clinical Professor and Director of Melanoma Program at University of California, San Francisco.

Dr. Robert Hamilton Pierce, also known as Rob, M.D., has been the Chairman of the Scientific Advisory Board, Consultant and Chief Scientific Strategist at OncoSec Medical Incorporated since June 18, 2016. Dr. Pierce served as the Chief Scientific Officer and Global Head of R&D at OncoSec Medical Incorporated since September 16, 2014 until June 18, 2016. Dr. Pierce served as the Chief Medical Officer of OncoSec Medical Incorporated since December 12, 2013 until September 16, 2014. He served as a Discovery Project Team Leader for two novel drug candidates. He served as an Executive Director of Merck Research Labs. Dr. Pierce served at Merck Research Labs -- Palo Alto where he spent almost seven years in leading a 20--person team, dedicated to developing disease-oriented and tissue-based translational medicine platforms. From 2001 to 2007, he served several leadership positions at the University of Rochester School of Medicine, including Director of the Autopsy Service at Strong Memorial Hospital. Dr. Pierce was at Merck Research abs. Dr. Pierce was responsible for contributions to multiple successful IND applications, including critical biomarker development programs such as the anti-PD-L1 immunohistochemistry assay supporting Merck's MK-3475 trials. He was instrumental in designing two Phase 2 anti-PD-1 (MK-3475) oncology studies. He focused on immunomodulatory receptor (IMR) programs. He practiced as a staff pathologist to develop the graduate curriculum in pathomechamism of disease. He was the principal investigator of a RO1-funded research lab, Dr. Pierce played an important role in the university's clinical and academic research programs. He is the co-author of over fifty peer-reviewed journal articles and book chapters and is a reviewer for numerous scientific journals as well as National Institute of Health grants. Dr. Pierce is well regarded for his career-long research into mechanisms of immune tolerance and has drug development experience. He is a key Member of the global development team behind Merck's FDA-designated breakthrough anti-PD-1 program (MK-3475). He was a Fulbright Award recipient. He studied Philosophy at the Albert-Ludwigs-University in Freiburg, Germany. He has been a Member of Scientific Advisory Board at Immunomic Therapeutics, Inc. since January 05, 2017. He serves as a Member of the Fred Hutchinson Cancer Research Center and the Scientific Director of the Immunopathology Lab. He is a graduate of Yale College and Brown University School of Medicine. Dr. Pierce received his Post-Doctoral Training at the University of Washington, Seattle, WA. He trained at Brown University School of Medicine in Providence, RI and received an Undergraduate Education at Yale University in New Haven, CT.

Tu Diep serves as the Vice President Operations of OncoSec. Tu started at OncoSec in September of 2014. Tu currently resides in Greater San Diego Area.

John Rodriguez serves as the Vice President of Product Engineering of OncoSec. John started at OncoSec in July of 2016. John currently resides in Greater San Diego Area.

Chris Twitty serves as the Chief Scientific Officer of OncoSec. Chris started at OncoSec in December of 2017. Chris currently resides in Greater San Diego Area.

Sharron Gargosky serves as the Chief Clinical and Regulatory Officer of OncoSec. Sharron started at OncoSec in February of 2016. Sharron currently resides in the Portland, Oregon Area.